NURSING · OBJECTIVE ASSESSMENT A+ VERIFIED
NU 578 Units 1–5 Exam — Complete
Official Exam
150 Questions Full Rationales Verified Answers
150 5 100%
QUESTIONS SECTIONS RATIONALES
Complete coverage Core exam domains Every answer explained
WHAT THIS COVERS
01 Principles of Pharmacology
02 Autonomic Nervous System Pharmacology
03 Cardiovascular Pharmacology
04 Renal and Endocrine Pharmacology
05 Central Nervous System Pharmacology
ABOUT THIS ASSESSMENT
Build mastery in advanced pharmacology — from pharmacokinetics and pharmacodynamics to autonomic nervous system agents, cardiovascular
pharmacotherapeutics, renal and endocrine pharmacology, and central nervous system drugs. This original study bank targets application and analysis
skills for NU 578 Units 1–5 Exam, with full rationales for every answer. For review use only; not an institutional proctored assessment.
PASSING SCORE LEVEL FORMAT
80% Advanced (Graduate Nursing) Application / Analysis
STUVIA ACTUAL EXAM Page 1
, SECTION 1: Principles of Pharmacology
Q1. A 68-year-old patient with CKD (eGFR 28) is prescribed a renally cleared drug. Reduced GFR most directly alters which
process, requiring dose adjustment?
A. GI absorption rate
B. Elimination half-life and steady-state level
C. Adipose distribution volume
D. First-pass hepatic metabolism only
Correct Answer: B
Rationale: Renal clearance determines elimination for renally excreted drugs. Low GFR prolongs half-life and elevates steady-state concentrations,
necessitating dose reduction.
Q2. A patient on warfarin starts a strong CYP2C9 inhibitor; INR rises. The inhibitor most likely affects which aspect of warfarin
disposition?
A. Increases renal secretion of S-warfarin
B. Accelerates GI absorption
C. Enhances plasma protein binding
D. Decreases hepatic metabolism of the potent S-enantiomer
Correct Answer: D
Rationale: S-warfarin is metabolized by CYP2C9. Inhibition reduces clearance, raising levels and INR. Binding and absorption changes are minor.
Q3. A CYP2D6 ultrarapid metabolizer is prescribed a prodrug requiring CYP2D6 activation. The most accurate clinical implication is:
A. Subtherapeutic effects requiring higher dose
B. No adjustment needed
C. Increased risk of toxicity from excess active metabolite
D. Avoid due to anaphylaxis risk
Correct Answer: C
Rationale: Ultrarapid metabolizers form active metabolites faster, raising toxicity risk (e.g., codeine). Poor metabolizers have subtherapeutic effects.
Q4. A critically ill patient on a highly protein-bound drug has albumin 1.8 g/dL. Free drug concentration will most likely:
A. Decrease because total concentration falls
B. Decrease due to expanded Vd
C. Remain unchanged
D. Increase because unbound fraction rises
Correct Answer: D
Rationale: Hypoalbuminemia increases free fraction of highly bound drugs, potentially amplifying effect until new steady state.
Q5. A drug undergoes extensive first-pass metabolism. After oral dosing, first-pass primarily influences:
A. Renal clearance independent of liver
B. Bioavailability and systemic exposure
C. Volume of distribution
D. Absorption rate only
Correct Answer: B
Rationale: First-pass reduces the fraction reaching systemic circulation (bioavailability). It does not determine renal clearance or Vd.
STUVIA ACTUAL EXAM · Page 2
, SECTION 1: Principles of Pharmacology
Q6. An older adult is prescribed a narrow-index drug with long half-life. Steady state is generally reached after how many half-lives?
A. 1–2
B. 3–5
C. 7–10
D. 12–15
Correct Answer: B
Rationale: Steady state is reached after ~3–5 half-lives of consistent dosing for most drugs.
Q7. Switching from IR to ER formulation of the same drug is expected to produce:
A. Higher Cmax and shorter Tmax
B. Complete loss of bioavailability
C. Identical Cmax/Tmax
D. Lower Cmax and prolonged Tmax
Correct Answer: D
Rationale: ER formulations release more slowly, lowering Cmax and prolonging Tmax while preserving AUC when dosed correctly.
Q8. A dual CYP3A4/P-gp inducer is given with a dual substrate. Net effect on systemic exposure is most likely:
A. Increased bioavailability and higher levels
B. Decreased bioavailability and lower levels
C. No change
D. Increased renal excretion only
Correct Answer: B
Rationale: Induction of CYP3A4 and P-gp both reduce systemic exposure of dual substrates.
Q9. In Child-Pugh C cirrhosis, a high-extraction drug given orally shows markedly higher bioavailability while IV clearance changes
little. Best explanation:
A. Reduced hepatic blood flow only
B. Portosystemic shunting bypassing first-pass
C. Increased protein binding
D. Enhanced renal clearance
Correct Answer: B
Rationale: Portosystemic shunts allow oral drug to bypass the liver, raising bioavailability of high-extraction drugs.
Q10. A drug's absorption is decreased by food. Expected concentration–time change:
A. Higher Cmax, shorter Tmax
B. Lower Cmax, delayed Tmax, possible lower AUC
C. No change
D. Conversion to inactive metabolite only with food
Correct Answer: B
Rationale: Food that delays emptying or binds drug lowers peak, prolongs Tmax, and may reduce AUC.
STUVIA ACTUAL EXAM · Page 3
NU 578 Units 1–5 Exam — Complete
Official Exam
150 Questions Full Rationales Verified Answers
150 5 100%
QUESTIONS SECTIONS RATIONALES
Complete coverage Core exam domains Every answer explained
WHAT THIS COVERS
01 Principles of Pharmacology
02 Autonomic Nervous System Pharmacology
03 Cardiovascular Pharmacology
04 Renal and Endocrine Pharmacology
05 Central Nervous System Pharmacology
ABOUT THIS ASSESSMENT
Build mastery in advanced pharmacology — from pharmacokinetics and pharmacodynamics to autonomic nervous system agents, cardiovascular
pharmacotherapeutics, renal and endocrine pharmacology, and central nervous system drugs. This original study bank targets application and analysis
skills for NU 578 Units 1–5 Exam, with full rationales for every answer. For review use only; not an institutional proctored assessment.
PASSING SCORE LEVEL FORMAT
80% Advanced (Graduate Nursing) Application / Analysis
STUVIA ACTUAL EXAM Page 1
, SECTION 1: Principles of Pharmacology
Q1. A 68-year-old patient with CKD (eGFR 28) is prescribed a renally cleared drug. Reduced GFR most directly alters which
process, requiring dose adjustment?
A. GI absorption rate
B. Elimination half-life and steady-state level
C. Adipose distribution volume
D. First-pass hepatic metabolism only
Correct Answer: B
Rationale: Renal clearance determines elimination for renally excreted drugs. Low GFR prolongs half-life and elevates steady-state concentrations,
necessitating dose reduction.
Q2. A patient on warfarin starts a strong CYP2C9 inhibitor; INR rises. The inhibitor most likely affects which aspect of warfarin
disposition?
A. Increases renal secretion of S-warfarin
B. Accelerates GI absorption
C. Enhances plasma protein binding
D. Decreases hepatic metabolism of the potent S-enantiomer
Correct Answer: D
Rationale: S-warfarin is metabolized by CYP2C9. Inhibition reduces clearance, raising levels and INR. Binding and absorption changes are minor.
Q3. A CYP2D6 ultrarapid metabolizer is prescribed a prodrug requiring CYP2D6 activation. The most accurate clinical implication is:
A. Subtherapeutic effects requiring higher dose
B. No adjustment needed
C. Increased risk of toxicity from excess active metabolite
D. Avoid due to anaphylaxis risk
Correct Answer: C
Rationale: Ultrarapid metabolizers form active metabolites faster, raising toxicity risk (e.g., codeine). Poor metabolizers have subtherapeutic effects.
Q4. A critically ill patient on a highly protein-bound drug has albumin 1.8 g/dL. Free drug concentration will most likely:
A. Decrease because total concentration falls
B. Decrease due to expanded Vd
C. Remain unchanged
D. Increase because unbound fraction rises
Correct Answer: D
Rationale: Hypoalbuminemia increases free fraction of highly bound drugs, potentially amplifying effect until new steady state.
Q5. A drug undergoes extensive first-pass metabolism. After oral dosing, first-pass primarily influences:
A. Renal clearance independent of liver
B. Bioavailability and systemic exposure
C. Volume of distribution
D. Absorption rate only
Correct Answer: B
Rationale: First-pass reduces the fraction reaching systemic circulation (bioavailability). It does not determine renal clearance or Vd.
STUVIA ACTUAL EXAM · Page 2
, SECTION 1: Principles of Pharmacology
Q6. An older adult is prescribed a narrow-index drug with long half-life. Steady state is generally reached after how many half-lives?
A. 1–2
B. 3–5
C. 7–10
D. 12–15
Correct Answer: B
Rationale: Steady state is reached after ~3–5 half-lives of consistent dosing for most drugs.
Q7. Switching from IR to ER formulation of the same drug is expected to produce:
A. Higher Cmax and shorter Tmax
B. Complete loss of bioavailability
C. Identical Cmax/Tmax
D. Lower Cmax and prolonged Tmax
Correct Answer: D
Rationale: ER formulations release more slowly, lowering Cmax and prolonging Tmax while preserving AUC when dosed correctly.
Q8. A dual CYP3A4/P-gp inducer is given with a dual substrate. Net effect on systemic exposure is most likely:
A. Increased bioavailability and higher levels
B. Decreased bioavailability and lower levels
C. No change
D. Increased renal excretion only
Correct Answer: B
Rationale: Induction of CYP3A4 and P-gp both reduce systemic exposure of dual substrates.
Q9. In Child-Pugh C cirrhosis, a high-extraction drug given orally shows markedly higher bioavailability while IV clearance changes
little. Best explanation:
A. Reduced hepatic blood flow only
B. Portosystemic shunting bypassing first-pass
C. Increased protein binding
D. Enhanced renal clearance
Correct Answer: B
Rationale: Portosystemic shunts allow oral drug to bypass the liver, raising bioavailability of high-extraction drugs.
Q10. A drug's absorption is decreased by food. Expected concentration–time change:
A. Higher Cmax, shorter Tmax
B. Lower Cmax, delayed Tmax, possible lower AUC
C. No change
D. Conversion to inactive metabolite only with food
Correct Answer: B
Rationale: Food that delays emptying or binds drug lowers peak, prolongs Tmax, and may reduce AUC.
STUVIA ACTUAL EXAM · Page 3
